Our xTAG® and MultiCode®-RTx Technologies serve a wide range of clinical applications, including infectious disease testing, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
The Versatility of Multiplex Antibody Titer Assays for COVID-19 and Beyond
The COVID-19 outbreak that began in Wuhan, China in December 2019 was marked by an increase in the number of cases showing pneumonia-like symptoms. It was not until about a month after the outbreak began that genomic analysis identified a novel coronavirus as the causative agent. With the emergence of new pathogen strains, genomic assays are not always able to detect new variants, and after an infection, may not be able to identify which pathogens were involved. However, with serological assays that pick up polyclonal antibody responses, the conservation of epitopes—even with new variants—make it possible to identify the different pathogens circulating in an epidemic.
Continue Reading >
Designed for use on the ARIES® System, the ARIES® SARS-CoV- 2 Assay is a moderate-complexity, sample-to-answer test that enables targeted SARS-CoV-2 detection. ARIES® consolidates the assay steps into a single workflow and reduces turnaround time with STAT and random batch testing.
CYTO (International Society for Advancement